MORF Morphic
- 29.485
- +0.775+2.70%
Morphic News
Analysts Offer Insights on Healthcare Companies: AstraZeneca (AZN), Accolade (ACCD) and Morphic Holding (MORF)
Stifel Nicolaus Remains a Hold on Morphic Holding (MORF)
Morphic Holding (MORF) Gets a Buy From RBC Capital
Morphic Holding's Buy Rating Affirmed: Promising Trials and Strong Financial Outlook
Analysts Offer Insights on Healthcare Companies: MoonLake Immunotherapeutics (MLTX) and Morphic Holding (MORF)
Morphic Holding: A Strong Buy on Robust Financials and Promising Clinical Trials
Morphic Holding Analyst Ratings
Morphic Holding: Strong Financials and Promising Clinical Trials Reinforce Buy Rating
Analysts Offer Insights on Healthcare Companies: Morphic Holding (MORF) and Vertex Pharmaceuticals (VRTX)
Analysts' Opinions Are Mixed on These Healthcare Stocks: Celldex (CLDX), Abbott Labs (ABT) and Morphic Holding (MORF)
Morphic Holding's Buy Rating Affirmed on Strong Clinical and Financial Prospects
Analysts Offer Insights on Healthcare Companies: Kymera Therapeutics (KYMR) and Morphic Holding (MORF)
BTIG Remains a Hold on Morphic Holding (MORF)
Morphic Holding Analyst Ratings
RBC Cuts Price Target on Morphic Holding to $76 From $80, Keeps Outperform, Speculative Risk
Promising Clinical Progress and Future Trials Reinforce Buy Rating for Morphic Holding's Stock (MORF)
Seigerman Recommends Buy for Morphic Holding Amid Solid Financial Position, Successful Clinical Trials, and Potential Future Catalysts
Analysts Offer Insights on Technology Companies: Morphic Holding (MORF), GoDaddy (GDDY) and Veeva Systems (VEEV)
BTIG Remains a Hold on Morphic Holding (MORF)
Promising Clinical Progress and Solid Financial Positioning Bolster Buy Rating for Morphic Holding
Analysis
Price Target
No Data
